|
Clozaril (Clozapine Tablets)
 This product requires a valid prescription
| |
|
Type |
Strength |
|
Quantity |
|
Price (USD) |
|
|
| |
|
FazaClo (clozapine, USP) Orally Disintegrating Tablets are prescribed to treat patients with schizophrenia who do not respond well to traditional medications. The FazaClo (clozapine, USP) Orally Disintegrating Tablets are designed to disintegrate in the mouth in about 15 to 30 seconds -- they are then swallowed with the saliva. FazaClo (clozapine, USP) Orally Disintegrating Tablets have a pleasant flavor, and can be taken discreetly, like a mint. FazaClo Orally Disintegrating Tablets have been shown to be bioequivalent to Novartis's Clozaril tablets on a milligram for milligram basis.
FazaClo (clozapine, USP) Orally Disintegrating Tablets is designed to disintegrate in the mouth in about 15 to 30 seconds with a pleasant mint flavor and is then swallowed reflexively in saliva. FazaClo (clozapine, USP) Orally Disintegrating Tablets also offers considerable convenience, as no water is required for administration. These clear advantages may be important in treating a disease such as schizophrenia since any barrier may present significant impedance for the patient.
FazaClo (clozapine, USP) Orally Disintegrating Tablets are well suited for active patients getting on with their lives because they offer considerable convenience. The FazaClo (clozapine, USP) Orally Disintegrating Tablets disintegrate quickly in the mouth and may be taken discreetly since no liquids are required for administration.
FazaClo (clozapine, USP) Orally Disintegrating Tablets are available in 25 mg and 100 mg tablets. The FazaClo dosage is determined by the health care practitioner on an individual basis. For treatment to be successful the patient must follow the doctor’s dosage instructions -- under no circumstances should the patient take more than the prescribed dose.
FazaClo (clozapine, USP) Orally Disintegrating Tablets are packaged in individual blisters and should remain in the unopened blister until the time of use. The FazaClo tablet should not be pushed through the foil. Just prior to use, peel back the foil from the blister and gently remove the tablet, being careful not to crush it. Immediately place the tablet in the mouth and allow it to disintegrate fully before swallowing. No liquid is needed.
If FazaClo tablets are split in half in order to deliver a half dose, the unused half-tablet should be safely destroyed.
When restarting treatment with FazaClo (clozapine, USP) Orally Disintegrating Tablets, even after a brief interval of interrupted dosing (i.e., two days or more since the last dose), it is recommended that the patient contact his or her health care practitioner for instructions.
The patient should contact his or her health care practitioner before discontinuing FazaClo (clozapine, USP) Orally Disintegrating Tablets or stopping or starting any other medication.
FazaClo (clozapine, USP) Orally Disintegrating Tablets should be stored at room temperature (59–86º F, 15-30º C) and protected from moisture. FazaClo (clozapine, USP) Orally Disintegrating Tablets should not be removed from the blister until immediately before use. FazaClo tablets should be kept out of the reach of children.
FazaClo Side Effects:
Should any side effect occur, including those listed below, report this to your health professionals right away. They will tell you whether the side effect of FazaClo (clozapine, USP) Orally Disintegrating Tablets can be expected to disappear as you get used to your medication, or they may ask you to adjust your dosage.
Agranulocytosis (a drop in white blood cell levels) is among the most serious side effects associated with clozapine therapy.
While taking clozapine (FazaClo) your blood will be tested for its white blood cell count and absolute neutrophil count every week, every other week, or every four weeks.
You should immediately report to your health practitioner any feelings of slowing down, weakness, fever, sore throat, sick-type feelings, mouth sores, or other possible signs of infection. Pay particular attention to reporting any flu-like complaints or other symptoms that might suggest you have an infection.
Other serious adverse reactions to FazaClo (clozapine, USP) Orally Disintegrating Tablets that have been reported include:
Seizures: There is a risk of developing seizures while taking FazaClo treatment, so you should avoid driving and any other hazardous activity while taking the medication. People with a history of seizures are also more likely to experience seizures with FazaClo (clozapine, USP) Orally Disintegrating Tablets therapy.
Myocarditis: The first month of therapy is also the period of greatest risk for a type of inflammation of the heart muscle called myocarditis. Thus, if you experience fatigue, rapid breathing, are easily out of breath, or have periods of sudden rapid heart beats, report these symptoms to your health professionals immediately.
Other Adverse Cardiovascular and Respiratory Effects: Especially in the beginning of treatment when your health professional is adjusting your dosage, there is a risk of feeling faint or dizzy when you stand up. This is called “orthostatic hypotension.” Therefore, during those first weeks, take your time getting out of bed or rising from a chair. Rapid or irregular heartbeat or difficulty breathing may also occur and may require a reduction in your dosage of FazaClo Orally Disintegrating Tablets, or treatment with an added medication.
Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs have an increased risk for death. FazaClo (clozapine, USP) Orally Disintegrating Tablets is not approved for treatment of patients with dementia-related psychosis.
|
|
|
|
